Women’s health start-up, Biorithm, is attempting to revolutionize maternity care. Through mobile technology and data science, the company aims to provide expectant women, wherever they are, more convenience and better information about their pregnancy. With the women’s health sector estimated to be worth $1 trillion by 2027, the Singapore-based company is part of a growing femtech industry that’s exciting investors.
Being pregnant and giving birth is safer than it’s ever been.
According to the World Health Organization, maternal deaths dropped by about 34% between 2000 and 2020.
Yet despite these improvements, a maternal death occurred almost every two minutes in 2020, and there are about 6,500 newborn deaths every day.
Singaporean medical technology startup Biorithm hopes to help solve this problem through mobile technology and data science.
“Women’s health care has not been innovated in decades, and it’s not addressed the needs of the modern woman,” said Amrish Nair, Biorithm’s co-founder and chief technology officer.
“Understanding this is how we can deliver healthcare to the mother at a point of convenience,” Nair told CNBC Tech: The Edge.
Founded by doctors and engineers, the company has developed a maternity care platform called Femom, which allows clinicians to deliver care to mother and baby, anytime, anywhere.
“Biorithm is really all about ending preventable poor outcomes in pregnancy, and we hope to achieve that through improving access to care by developing remote monitoring technologies, allowing patients to take the hospital to their home,” Nair said.
Watch the video above to see how Femom works.
